| Abstract: |
Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death. The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clinical responses. © 2007 by Cold Spring Harbor Laboratory Press. |
| Keywords: |
protein kinase b; review; sorafenib; erlotinib; sunitinib; nonhuman; temozolomide; glioma; brain neoplasms; neoplasm staging; cancer grading; cell proliferation; animals; imatinib; unindexed drug; vasculotropin receptor; apoptosis; proteasome; models, biological; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor; platelet derived growth factor receptor; neovascularization, pathologic; necrosis; cetuximab; protein p53; cancer research; carcinogenesis; stem cell; monoclonal antibody; cancer genetics; chromosome aberration; glioma cell; glioblastoma; death receptor 4; death receptor 5; mammalian target of rapamycin; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; gefitinib; pazopanib; vandetanib; vatalanib; transcription factor sp1; protein kinase c; neoplasm invasiveness; disease models, animal; tyrosine kinase inhibitor; cell cycle regulation; neural stem cells; steroid receptor; astrocytoma; everolimus; lapatinib; protein mdm2; gene regulatory networks; cancer stem cells; animals, genetically modified; 6 [4 (4 ethyl 1 piperazinylmethyl)phenyl] 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidine; genetically engineered models; 4 (4 fluoro 2 methyl 5 indolyloxy) 6 methoxy 7 [3 (1 pyrrolidinyl)propoxy]quinazoline
|
